Company Overview of Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In...
450 West 15th Street
New York, NY 10011
Founded in 2002
Key Executives for Intercept Pharmaceuticals, Inc.
Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $1.0M
President of International
Total Annual Compensation: $554.4K
Chief Medical Officer and Executive Vice President of Development
Total Annual Compensation: $644.0K
Chief Business and Strategy Officer
Total Annual Compensation: $546.0K
Compensation as of Fiscal Year 2015.
Intercept Pharmaceuticals, Inc. Key Developments
Intercept Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-04-2017 11:20 AM
Mar 21 17
Intercept Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-04-2017 11:20 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.
Intercept Pharmaceuticals, Inc. Presents at Oppenheimer 27th Annual Healthcare Conference, Mar-21-2017 03:55 PM
Mar 16 17
Intercept Pharmaceuticals, Inc. Presents at Oppenheimer 27th Annual Healthcare Conference, Mar-21-2017 03:55 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, New York, United States.
Intercept Pharmaceuticals, Inc. Announces National Institute for Health and Care Excellence Approves Ocaliva (Obeticholic Acid) for Routine Use by the National Health Service in England, Wales and Northern Ireland
Mar 2 17
Intercept Pharmaceuticals, Inc. announced that the National Institute for Health and Care Excellence (NICE) has approved Ocaliva (obeticholic acid) for routine use by the National Health Service (NHS) in England, Wales and Northern Ireland. Ocaliva has been conditionally approved in the European Union for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. The NHS is expected to make Ocaliva available to patients with PBC within 90 days of NICE's final appraisal publication and Intercept will work with local reimbursement authorities to help ensure eligible patients obtain access. The most commonly reported adverse reactions were pruritus (63%) and fatigue (22%). Adverse reactions leading to discontinuation were 1% in the Ocaliva titration arm and 11% in the Ocaliva 10 mg arm. The most common adverse reaction leading to discontinuation was pruritus. The majority of pruritus occurred within the first month of treatment and tended to resolve over time with continued dosing.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|